Celldex Therapeutics (NASDAQ:CLDX) Hits New 1-Year Low – What’s Next?

Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s stock price hit a new 52-week low on Thursday . The stock traded as low as $20.91 and last traded at $22.26, with a volume of 920471 shares. The stock had previously closed at $21.91.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Thursday, December 19th. UBS Group started coverage on shares of Celldex Therapeutics in a research report on Thursday. They set a “buy” rating and a $44.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Celldex Therapeutics has an average rating of “Moderate Buy” and an average target price of $60.22.

Celldex Therapeutics Stock Down 1.6 %

The stock has a 50 day simple moving average of $24.79 and a 200-day simple moving average of $29.98.

Institutional Trading of Celldex Therapeutics

Several institutional investors have recently made changes to their positions in the business. EverSource Wealth Advisors LLC boosted its stake in Celldex Therapeutics by 215.7% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 878 shares during the period. KBC Group NV lifted its holdings in shares of Celldex Therapeutics by 31.2% in the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 495 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Celldex Therapeutics during the fourth quarter worth $81,000. AlphaQuest LLC grew its stake in Celldex Therapeutics by 171.0% during the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 2,705 shares in the last quarter. Finally, Aquatic Capital Management LLC purchased a new position in Celldex Therapeutics during the fourth quarter valued at $121,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.